Efficacy and safety of adalimumab in ulcerative colitis refractory to conventional therapy in routine clinical practice

Journal of Crohn's and Colitis

Volumn 10, Issue 1, 2016, Pages 26-30

  Bálint, Anita ^a   Farkas, Klaudia ^a   Palatka, Károly ^b   Lakner, Lilla ^c   Miheller, Pál ^d   Rácz, István ^e   Hegede, Gábor ^f   Vincze, Áron ^g   Horváth, Gábor ^h   Szabó, Andrea ^e   Nagy, Ferenc ^a   Szepes, Zoltán ^a   Gábor, Zoltán ^h   Zsigmond, Ferenc ⁱ   Zsóri, Ágnes ^j   Juhász, Márk ^d   Csontos, Ágnes ^d   Szucs, Mónika ^a   Bor, Renáta ^a   Milassin, Ágnes ^a   Rutka, Mariann ^a   Molnár, Tamás ^a   more..

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c Markusovszky University Teaching Hospital   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e Petz Aladar Country Hospital   (Hungary)

^f Péterfy Sándor Street Hospital Clinic and Emergency Center ^*  (Hungary)

^g UNIVERSITY OF PÉCS   (Hungary)

^h Semmelweis Hospital   (Hungary)

ⁱ Military Hospital   (Hungary)

^j Kazincbarcika Hospital   (Hungary)

more..

Author keywords

adalimumab; continuous clinical response; mucosal healing; Ulcerative colitis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; INFLIXIMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL PRACTICE; COLON RESECTION; COLONOSCOPY; DRUG DOSE INCREASE; DRUG DOSE INTENSIFICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEOPLASM; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS; CLINICAL TRIAL; COHORT ANALYSIS; COLITIS, ULCERATIVE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; HUNGARY; INTESTINE MUCOSA; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT SAFETY; PHYSIOLOGY; RECURRENT DISEASE; RISK ASSESSMENT; TERTIARY CARE CENTER; TREATMENT OUTCOME; WOUND HEALING; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HUNGARY; INTESTINAL MUCOSA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT SAFETY; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; TERTIARY CARE CENTERS; TREATMENT OUTCOME; WOUND HEALING; YOUNG ADULT;

EID: 84963724543     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv169     Document Type: Article

References (14)

1. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort [IBSEN Study]. Scand J Gastroenterol 2009;44:431-40
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
3. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7
4. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65
5. Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology 2015;148:37-51
6. Kornbluth AA. Adalimumab: another treatment option for moderate-tosevere UC. Gastroenterol Hepatol 2013;9:321
7. Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008;28:966-72
8. Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009;15:1302-7
9. Suzuki Y, Motoya S, Hanai H, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol 2014;49:283-94
10. Gies N, Kroeker KI, Wong K, Fedorak RN. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010;32:522-8
11. Tursi A, Elisei W, Picchio M, et al. Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first 'real-life' experience in primary gastroenterology centers in Italy. Ann Gastroenterol 2014;27:369-73
12. Taxonera C, Estelles J, Fernandez-Blanco I, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther 2011;33:340-8
13. Garcia-Bosch O, Gisbert JP, Canas-Ventura A, et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis 2013;7:717-22
14. Armuzzi A, Biancone L, Daperno M, et al. Adalimumab in active ulcerative colitis: a 'real-life' observational study. Dig Liver Dis 2013;45:738-43